TrialNature communications2021

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

Joris L Vos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.